The Pentagon signed a production framework with Lockheed Martin for the AIM-260 — On September 17, 2026 the War Department announced a framework agreement with Lockheed Martin to expand production capacity for the AIM-260 Joint Advanced Tactical Missile, the classified long-range air-to-air weapon intended to replace AMRAAM on the F-22 and F-35. Officials were explicit that it is neither a contract nor an order: no dollar value, no quantity, no timeline. It is a demand signal meant to justify capacity and workforce investment down the supply chain, laying groundwork for a multiyear procurement that would need congressional approval.

Australia has committed roughly US$520 million to buy the missile for the Royal Australian Air Force, making it the first export customer for a weapon whose existence was barely acknowledged until recently. The interesting part is not Lockheed. It is that the department keeps reaching for this instrument — a non-binding capacity commitment aimed past the prime at the sub-tier — and that the seeker, solid-rocket-motor and airframe suppliers who would have to build the capacity are mostly not the companies whose names appear in the announcement.

Indonesia is routing every coal, palm oil and ferroalloy export through one new state company — PT Danantara Sumberdaya Indonesia began assuming operational control of strategic commodity exports on September 1, 2026, with the second and binding phase scheduled for January 1, 2027, after which registered exporters lose the ability to ship independently. Indonesia moves roughly 350 to 400 million tonnes of thermal coal a year, on the order of 35 to 40 percent of the seaborne trade, plus the world’s largest palm oil volumes.

The stated purpose is to stop under-invoicing and capital flight, which Indonesian officials have sized at $908 billion across 1991 to 2024. The unstated problem is working capital: buying and reselling that volume is estimated to require around $31 billion a year, and DSI is a newly created entity with no trading track record. Newcastle thermal coal sat near $145 a tonne in mid-September 2026, three-month highs but hardly a crisis price, which suggests the execution risk in a January 1 handover is not yet in the number.

European ammonia is underwater at current gas prices — September Dutch TTF traded above €66.50 per megawatt hour, equivalent to more than $22.70 per million BTU, against a US Henry Hub spot price of $2.79 for the week ending September 11, 2026. At European gas costs, indicative break-even for an efficient plant runs near $837 a tonne for ammonia and $605 for urea, before emissions costs. Urea has been trading in the $415 to $475 range. AGF Nitrogen, the continent’s second-largest producer, has publicly warned it is considering curtailing ammonia capacity and called the gas price a threat to European food security.

EU mineral fertiliser output is still 10 to 15 percent below pre-2022 levels, a gap that opened in the last gas crisis and never closed. Two things follow if plants actually idle: nitrogen supply tightens into the spring application season, and European merchant carbon dioxide, which is largely a byproduct of ammonia synthesis, goes short again — the 2021 and 2022 pattern that hit food processing, brewing and meat plants before it hit anything financial.

Roughly 70 percent of US farmers could not afford all the fertiliser they wanted for the 2026 crop — An American Farm Bureau Federation survey found that about seven in ten farmers reported being unable to buy the full amount of fertiliser their 2026 acreage called for. Underapplication does not show up in this year’s harvest data; it shows up as depleted soil nutrient banks and softer yields the following season.

That matters because it points the opposite way from the supply-shock narrative. Demand destruction caps how far nitrogen prices can run, and it quietly moves the consequence from a 2026 fertiliser story to a 2027 grain story — at the same time as NOAA is forecasting a very strong El Niño for the 2026-27 winter.

Avio says it is fielding customers SpaceX turned away — Avio chief executive Giulio Ranzo said the Italian launch provider has seen an influx of customers who could not secure a slot with SpaceX, describing SpaceX as having “gone captive” — meaning its manifest is consumed by its own constellation and anchor customers rather than open commercial demand. Avio operates Vega-C and is taking over its commercialisation from Arianespace.

Avio shares closed September 17, 2026 at €28.70, 55.6 percent below their one-year high and down 16.6 percent over three months. A launch provider being handed demand it could not win on price or cadence is a fundamentally different situation from the one that de-rated it, and the checkable question is whether any of this has reached the backlog disclosure yet or is still one executive’s characterisation of his own order book.

European NewSpace funding passed €1 billion in a single month — EnduroSat’s raise pushed the running total of European commercial space funding above €1 billion for September 2026 alone, a level the sector has not previously reached in a month. Separately, ESA opened the next phase of IRIS² evolution work on low-LEO activities, and Satrec Initiative was contracted to build ten 10-centimetre-class optical satellites for a Hanwha constellation.

Capital arriving at this rate into a set of companies that are almost entirely private raises the usual proxy question: which listed European suppliers of optics, structures, propulsion and ground segment sit downstream of all of it, and are any of them priced as though the funding environment still looks like it did two years ago.

The Army has committed $2.2 billion to on-base nuclear microreactors, and the Navy has picked its first site — In late August 2026 the Army’s Janus program selected Antares Nuclear, BWXT, General Atomics, Radiant and Westinghouse for awards of up to a combined $2.2 billion to own, build and operate microreactors at Fort Bragg, Fort Campbell, Fort Hood, Fort Benning and Fort Drum. The money spans fiscal 2027 through 2031 and pays on milestones rather than in advance. On September 9, 2026 the War Department added the Navy’s first shore-based microreactor, to be installed at Naval Weapons Station Crane, Indiana no later than September 2028.

The Crane vendor has not been named, and neither has the cost or the funding line. Of the five Janus awardees only two are inside listed companies, which is the recurring shape of this program: the government keeps writing large cheques to entities a public investor cannot buy, and the expression, if there is one, sits in fuel, forgings, instrumentation and licensing services rather than in the reactor developers.

Prediction markets are pricing the October Fed meeting as a coin flip between nothing and a hike — As of September 17, 2026, Polymarket’s October Federal Reserve decision market showed roughly 50.5 percent on no change and 49.5 percent on a 25 basis point increase, with a cut priced at under one percent across both the 25 and 50 basis point outcomes. Twenty-four hour volume on the event was above $2.6 million.

Prediction market prices are expectations, not forecasts, and they are frequently wrong. What is notable is the shape rather than the level: the distribution has no downside tail at all, which is a different regime from the one most portfolio construction still assumes, and it is arriving alongside Brent above $110 and record US diesel prices.

The ADHD stimulant shortage has spread across manufacturers with a common stated cause — FDA’s drug shortage database, updated September 16, 2026, lists current shortages of lisdexamfetamine capsules and chewable tablets, extended-release methylphenidate, and mixed amphetamine salts across Elite Laboratories, Apotex, Novadoz, Vertical, Trigen, Sunrise and Oryza. Several entries give the reason as a shortage of an active pharmaceutical ingredient; one gives demand increase.

When many unrelated finished-dose manufacturers go short on the same molecules citing API supply, the constraint is upstream of all of them — either a small number of API plants or the DEA quota that caps how much controlled substance may be produced at all. Which of those two it is determines whether this resolves commercially or requires a regulatory decision.

A separate set of large-volume sterile fluids is short at one manufacturer — The same FDA update lists dextrose 5%, 10% and 50% injection, sterile water irrigant and amino acid injection as current shortages, with Otsuka ICU Medical named on most of the entries and manufacturing discontinuation given as the reason on two. Amino acid injection is the base of parenteral nutrition for patients who cannot eat.

Large-volume parenterals are a low-margin, high-weight, few-supplier business, which is exactly why the 2024 hurricane damage to a single North Carolina plant produced a national rationing event. The question worth checking is whether these entries represent new supply loss or the administrative tail of shortages already in progress, because the two have very different implications for hospital operators and for the handful of companies that can make these products.